Molecular markers play an increasingly important role in managing urologic cancers. In this test-specific episode of the "Answers From the Lab" podcast, Sounak Gupta, M.B.B.S., Ph.D., explains why Mayo Clinic Laboratories' urologic NGS panels are a cost-effective way to inform prognosis and individualized treatment.

"The new test panels fill a void between single gene assays and our large solid tumor panel," Dr. Gupta says. "Within a small, targeted panel, we can address a lot of questions collectively."

Mayo Clinic urologists, oncologists, and geneticists helped determine which genes to include. "We've tried to cover the most relevant diagnostic, therapeutic and prognostic biomarkers in a disease-specific manner for kidney, bladder, and prostate cancer," Dr. Gupta says.

Some of the panels (noted below) also evaluate microsatellite instability status to help guide immunotherapy selection. "These very carefully curated panels are tools for multiple groups that help us better serve our patients," Dr. Gupta says.

Listen to learn more about Mayo Clinic Laboratories' MayoComplete urologic panels.

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

MCKCP | MayoComplete Kidney Cancer Panel, Next-Generation Sequencing, Tumor

• Provides diagnostic, prognostic, and therapeutic insights based on assessment of 30 genes.
• Evaluates for microsatellite instability status.

MCBPP | MayoComplete Bladder and Prostate Cancer Panel, Next-Generation Sequencing, Tumor

• Provides diagnostic, prognostic, and therapeutic insights based on assessment of 39 genes.
• Evaluates for microsatellite instability status.

MCFRC | MayoComplete Renal Cell Carcinoma with Fibromyomatous Stroma Panel, Next-Generation Sequencing, Tumor

• Provides diagnostic insights based on assessment of four genes.

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less